Aula 5 - Desenvolvimento de tecnologia terapêutica para a COVID-19

Aula retirada do ar conforme cronograma do curso!

Vídeos recomendados:

• https://www.youtube.com/watch?v=mBQQ3ZmdlvA&feature=youtu.be

• https://portal.fiocruz.br/video/uso-de-animais-de-laboratorio-em-pesquisas-fiocruz-brasilia

• https://drauziovarella.uol.com.br/videos/coluna/estudos-clinicos-coluna-58/

• https://www.youtube.com/watch?v=gh2fjLQ7EIM

Referências (Parte 1):

Livros:

• Goodman & Gilman. As bases farmacológicas da terapêutica. 13a ed. Rio de Janeiro, McGraw-Hill, 2018.

• Rang & Dale. Farmacologia. 8a ed. Rio de Janeiro: Elsevier, 2016. Seizi, O. Fundamentos da toxicologia. 4a ed. São Paulo: Atheneu, 2014.

Artigos:

• Dhama K et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vaccines & Immunotherapeutics, 2020. doi.org/10.1080/21645515.2020.1735227.

• Falzarano D et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 2014;10(8):e1004250. doi:10.1371/journal.ppat.1004250.

• Munster VJ et al. Pneumonia from human coronavirus in a macaque model. N Engl J Med. 2013. doi:10.1056/NEJMc1215691.

• Roberts A et al. Animal models and vaccines for SARS-CoV infection. Virus Res., 2008. doi:10.1016/j.virusres.2007.03.025.

• Sanders JM, et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review. Clinical Review& Education, 2020. doi:10.1001/jama.2020.6019.

• Tu UF, et al. A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int J Molecular Sciences, 2020.

• Yang XH, et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavírus infection. Comp Med. 2007.

• Zhou Y, et al. Prospects for a MERS-CoV spike vaccine. Expert Rev Vaccines. 2018;17(8):677–86. doi:10.1080/14760584.2018.1506702.

Referências (Parte 2):

• SANDERS, James M. et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Jama, 2020.

• HOFFMANN, Markus et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020.

• WILLIAMSON, Brandi et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. BioRxiv, 2020.

• FU, Binqing; XU, Xiaoling; WEI, Haiming. Why tocilizumab could be an effective treatment for severe COVID-19?. Journal of translational medicine, v. 18, n. 1, p. 1-5, 2020.

• GAUTRET, Philippe et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, p. 105949, 2020.

• WORLD HEALTH ORGANIZATION et al. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. World Health Organization, 2020.

Lembrem-se:

• O Estudo Dirigido referente a esta aula encontra-se neste link: https://forms.gle/GGSwy2A5Jcha43nU7 e deve ser respondido até o dia 15/05/2020 (6ª feira).

Obrigada! Até a próxima aula!

Por Jéssica Perini e Marllow Claudino